Follicle Stimulating Hormone (FSH) Market:By Product Type (Recombinant Follicle Stimulating Hormone, Urinary follicle Stimulating Hormone), By Application (Assisted Reproductive technology, Infertility Treatment), By End Users (Hospitals, Gynecology Clinics, Infertility Centers) and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

The global Follicle Stimulating Hormone (FSH) Market size is expected to reach USD 3.4 billion by 2028, at a CAGR of 4.6% during the forecast period 2023-2029. Follicle stimulating hormone (FSH) is a gonadotropic hormone secreted by anterior pituitary gland. It helps in the development of pubertal maturation, and reproductive process. FSH regulates the functions of testes and ovaries. Insufficiency of follicle stimulating hormone may cause the subfertility or infertility in women and men.  However, stringent regulatory guidelines for product approval, alternative procedures for infertility, and lack of awareness in underdeveloped countries may restrain the growth of Follicle Stimulating Hormone (FSH) Market. FSH is a glycoprotein that promotes egg growth in female ovaries and sperm generation in male testes. FSH affects the ovarian follicles directly, prompting them to develop and produce oestrogen. It also causes the Mullerian ducts to regress, triggering gonadal growth, maturation, and steroidogenesis in both sexes by activating particular Leydig cells to generate testosterone or a Mullerian inhibitory chemical. It can also be used in conjunction with human chorionic gonadotropin to induce ultimate oocyte maturation in the clinic (hCG). In addition, a growing number of research utilising animal models such as mice have revealed that LH plays a role in boosting neurological function by enhancing synaptic plasticity and memory. The primary goals of an FSH test in women are to detect abnormalities in menstrual cycles in young females or to suspect the onset of menopause in middle-aged women. FSH tests, like clinical investigative investigations for women, can assist determine a man's sperm count. As the medical sector undergoes significant transition, it piques healthcare professionals' interest in clinical trials involving follicles and hormones in people. The commercial exposure of diagnostic treatments and procedures is induced by the use of standard specimens and funding for research projects. The impacts of climate change and the external environment on human health and follicles are also examined in a predicted study.

Follicle Stimulating Hormone Fsh Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4.6%

Largest Market

North America

Fastest Growing Market

Europe
Dynamics Follicle Stimulating Hormone Market Dynamics

Growing incidence of infertility in both men and women due to change in lifestyle, rise in R&D for the synthesis of follicle stimulating hormone (FSH), growing awareness about the follicle stimulating hormones among physicians, and increase in healthcare expenditure are anticipated to fuel the growth of follicle stimulating hormone market over the forecast period.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Follicle Stimulating Hormone Fsh Market Segmentation

Product Type
  • Recombinant Follicle Stimulating Hormone
  • Urinary Follicle Stimulating Hormone
Application
  • Assisted Reproductive Technology
  • Infertility Treatment
End User
  • Hospitals
  • Gynecology Clinics
  • Infertility Centers

Frequently Asked Questions

The global Follicle Stimulating Hormone (FSH) Market size is expected to reach USD 3.4 billion by 2029

Merck Serono (Germany), Merck Sharp & Dohme Corp. (Merck & Co. Inc.) (U.S.), Ferring B.V. (Switzerland), IBSA Institut Biochimque SA (Switzerland)

North America is the fastest-growing region for the follicle-stimulating hormone (FSH) market          

follicle stimulating hormone (FSH) market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

The key opportunities for the follicle stimulating hormone (FSH) market include its use in fertility treatments, menopausal hormone therapy, and potential applications in diagnosing certain medical conditions, driving market growth.

1.Executive Summary
2.Global Follicle Stimulating Hormone (FSH) Market Introduction 
2.1.Global Follicle Stimulating Hormone (FSH) Market  - Taxonomy
2.2.Global Follicle Stimulating Hormone (FSH) Market  - Definitions
2.2.1.Product Type
2.2.2.Application
2.2.3.End User
2.2.4.Region
3.Global Follicle Stimulating Hormone (FSH) Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Follicle Stimulating Hormone (FSH) Market Analysis, 2018-2022 and Forecast 2023-2029
4.1.  Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Follicle Stimulating Hormone (FSH) Market  By Product Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Recombinant Follicle Stimulating Hormone
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Urinary Follicle Stimulating Hormone
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6.Global Follicle Stimulating Hormone (FSH) Market  By Application, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Assisted Reproductive Technology
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Infertility Treatment
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7.Global Follicle Stimulating Hormone (FSH) Market  By End User, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Hospitals
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Gynecology Clinics
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Infertility Centers
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Follicle Stimulating Hormone (FSH) Market  By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Follicle Stimulating Hormone (FSH) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Recombinant Follicle Stimulating Hormone
9.1.2.Urinary Follicle Stimulating Hormone
9.2.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Assisted Reproductive Technology
9.2.2.Infertility Treatment
9.3.  End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospitals
9.3.2.Gynecology Clinics
9.3.3.Infertility Centers
9.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Follicle Stimulating Hormone (FSH) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Recombinant Follicle Stimulating Hormone
10.1.2.Urinary Follicle Stimulating Hormone
10.2.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Assisted Reproductive Technology
10.2.2.Infertility Treatment
10.3.  End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospitals
10.3.2.Gynecology Clinics
10.3.3.Infertility Centers
10.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
10.4.7.
11.Asia Pacific (APAC) Follicle Stimulating Hormone (FSH) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Recombinant Follicle Stimulating Hormone
11.1.2.Urinary Follicle Stimulating Hormone
11.2.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Assisted Reproductive Technology
11.2.2.Infertility Treatment
11.3.  End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospitals
11.3.2.Gynecology Clinics
11.3.3.Infertility Centers
11.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Follicle Stimulating Hormone (FSH) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Recombinant Follicle Stimulating Hormone
12.1.2.Urinary Follicle Stimulating Hormone
12.2.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Assisted Reproductive Technology
12.2.2.Infertility Treatment
12.3.  End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospitals
12.3.2.Gynecology Clinics
12.3.3.Infertility Centers
12.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Follicle Stimulating Hormone (FSH) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Recombinant Follicle Stimulating Hormone
13.1.2.Urinary Follicle Stimulating Hormone
13.2.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Assisted Reproductive Technology
13.2.2.Infertility Treatment
13.3.  End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospitals
13.3.2.Gynecology Clinics
13.3.3.Infertility Centers
13.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Merck Serono (Germany)
14.2.2.Merck Sharp & Dohme Corp. (Merck & Co. Inc.) (U.S.)
14.2.3.Ferring B.V. (Switzerland)
14.2.4.IBSA Institut Biochimque SA (Switzerland)
14.2.5.Livzon Pharmaceutica Group Inc. (Hong Kong)
14.2.6.Techwell Inc. (U.S.)
14.2.7.Gedeon Richter Plc (Hungary)
14.2.8.GenScience Pharmaceuticals Co. Ltd. (Changchun High & New Tech) (China)
15. Research Methodology 
16. Appendix and Abbreviations 
  • Merck Serono (Germany)
  • Merck Sharp & Dohme Corp. (Merck & Co. Inc.) (U.S.)
  • Ferring B.V. (Switzerland)
  • IBSA Institut Biochimque SA (Switzerland)
  • Livzon Pharmaceutica Group Inc. (Hong Kong)
  • Techwell Inc. (U.S.)
  • Gedeon Richter Plc (Hungary)
  • GenScience Pharmaceuticals Co. Ltd. (Changchun High & New Tech) (China)

Adjacent Markets